Listar por tema "MDSCs"
Mostrando ítems 1-1 de 1
-
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ...